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Abstract Phosphatidylinositol 5-phosphate (PtdIns5P), a novel
inositol lipid, has been shown to be the major substrate for the
type II PtdInsP kinases (PIPkins) [Rameh et al. (1997) Nature
390, 192^196]. A PtdInsP fraction was prepared from cell
extracts by neomycin chromatography, using a protocol devised
to eliminate the interaction of acidic solvents with plasticware,
since this was found to inhibit the enzyme. The PtdIns5P in this
fraction was measured by incubating with [Q-32P]ATP and
recombinant PIPkin IIK, and quantifying the radiolabelled
PtdInsP2 formed. This assay was used on platelets to show that
during 10 min stimulation with thrombin, the mass level of
PtdIns5P increases, implying the existence of an agonist-
stimulated synthetic mechanism. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Phosphatidylinositol phosphate (PtdInsP) kinases (PIPkins)
are a growing family of enzymes, which phosphorylate
PtdInsPs to form PtdInsP2s (for review, see [1]). The type II
PIPkins were ¢rst recognised as being distinct in their sub-
strate speci¢city by Rameh et al. [2], who showed that they
phosphorylate not PtdIns4P as do the type I isozymes, but
PtdIns5P instead, o¡ering an alternative pathway for the syn-
thesis of PtdIns(4,5)P2. Evidence was also presented for the
natural occurrence of PtdIns5P in cells [2].
The principal product of both type I and type II PIPkins,
PtdIns(4,5)P2, is a crucial molecule involved in many signal-
ling pathways [1]. It is the precursor for PtdIns(3,4,5)P3, Ins-
(1,4,5)P3 and diacylglycerol, and also has many cellular func-
tions of its own, its principal roles being actin cytoskeleton
assembly regulation [3], Golgi function [4], vesicle formation
and endocytosis [5], potassium channel regulation (for review,
see [6]) and exocytosis [7]. Thus the 4-OH phosphorylation of
PtdIns5P could represent an alternative pathway to
PtdIns(4,5)P2, perhaps localised for a speci¢c individual func-
tion of that lipid [1].
However, it may also be that PtdIns5P is a signalling mol-
ecule in its own right, and thus that the function of type II
PIPkins is to remove it. We currently know little about the
production or the regulation of metabolism of PtdIns5P. As a
means of gaining insight into the function of this lipid, and
also to provide a basis for further investigation into the type
II PIPkins, we have developed a mass assay capable of deter-
mining accurately the levels of PtdIns5P in platelets. We have
followed quantitatively the changes in PtdIns5P elicited by
thrombin, an activator of platelets that is known to a¡ect
lipid levels, including PtdIns(4,5)P2 [8^10]. This assay will
also be suitable for application in other cell systems.
2. Materials and methods
2.1. Materials
Carrier-free, bovine serum albumin (BSA)-free human thrombin,
controlled-pore glass beads and triethylamine were from Sigma Chem-
ical Co. (St. Louis, MO, USA). Pure synthetic PtdIns5P was from
Echelon Research Laboratories (Salt Lake City, UT, USA). PtdIns
was from Doosan Serdary (Englewood Cli¡s, NJ, USA). [Q-32P]ATP
was from New England Nuclear (Boston, MA, USA). [3H]Ins(1,4,5)P3
was from Amersham (Amersham, UK). Silica-coated thin-layer chro-
matography (TLC) plates were from Merck KGaA (Darmstadt, Ger-
many). PI-cellulose plates were from Mackery-Nagel GmbH and Co.
KG (Du«ren, Germany). Whatman 3MM paper and the Partisil-10
SAX high performance liquid chromatography (HPLC) column
were from Whatman International (Torrance, CA, USA). Folch lipids
were prepared in-house according to the method of Folch [11].
2.2. Platelet lipid extraction
Platelets were extracted from fresh whole human blood from
healthy donors as described previously [12]. The platelets were incu-
bated at 37‡C for 5 min, then CaCl2 was added to 2 mM and they
were incubated for a further 5 min prior to experimental use.
Duplicate 90 Wl platelet samples were added to 1 NIH-unit throm-
bin (carrier- and BSA-free) in plastic microtubes, and incubated at
37‡C as required. Thrombin was omitted from control samples. To
halt the stimulation, samples were transferred to glass microtubes
containing 12.5 Wl 70% (v/v) perchloric acid. Lipid extraction was
carried out according to Bligh and Dyer [13] by adding 500 Wl 1:1
(v/v) CHCl3 :CH3OH to each sample, followed by pure PtdIns5P to
some tubes as a routine check on recovery, and 1 NIH-unit of throm-
bin to control samples. Phases were separated by the addition of 125 Wl
of 2.4 N HCl, and samples were vortexed thoroughly and centrifuged
at 10 000Ug for 2 min at room temperature. Most (400 Wl) of the
upper phase was removed and discarded and replaced with 400 Wl
theoretical upper phase (3:48:47 (v/v) CHCl3 :CH3OH:1 M HCl).
This washing was repeated twice further. The ¢nal lower phase was
removed and saved, and replaced with 175 Wl theoretical lower phase
(86:14:1 (v/v) CHCl3 :CH3OH:1 M HCl) which was likewise vor-
texed, centrifuged and removed, and pooled with the ¢rst lower phase
extraction. Duplicate samples were then pooled and dried by vacuum
centrifugation.
2.3. Lipid puri¢cation
Neomycin-linked glass beads were prepared as described by Schacht
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[14]. Beads were aliquoted into glass microtubes to a packed volume
of 25 Wl, and storage solvent decanted from the pellet. Beads were pre-
equilibrated with 120 Wl 1:1 (v/v) CHCl3 :CH3OH by mixing, incubat-
ing for 30 min at room temperature, mixing, centrifuging (10 000Ug,
1 min) and pouring away. This was repeated with 120 Wl CHCl3.
Samples were loaded onto beads in 20 Wl 1:1 (v/v) CHCl3 :CH3OH,
then the empty sample tubes were rinsed with a further 20 Wl CHCl3,
which was also transferred to the beads. Carrier lipid (5 nmol PtdIns)
was added to the beads in a volume of 10 Wl 1:1 (v/v) CHCl3 :CH3OH.
Loaded beads were washed ¢rst with 250 Wl of a formate solvent
(5:10:2 (v/v) CHCl3 :CH3OH:H2O, 50 mM ammonium formate ¢nal)
according to Palmer [15] to remove all non-inositide lipids, vortexed,
incubated at room temperature for 1 h, vortexing after 30 min and at
the end of incubation, and then centrifuged as earlier and the solvent
poured away. This was repeated. PtdInsP lipids were eluted ¢nally by
washing the beads using a solvent composed of 2:6:3 (v/v)
CHCl3 :CH3OH:2 M triethylamine bicarbonate (TEAB) (¢nal
TEAB concentration 0.55 M) using the working protocol as for the
earlier ammonium formate solvent, ¢rstly with 250 Wl then 100 Wl
solvent, pooling the eluates in plastic microtubes. Eluates were dried
down overnight. The 2 M TEAB was prepared fresh each time by
bubbling CO2 through a 2 M solution of triethylamine on ice until its
pH was 4.5.
2.4. Lipid phosphorylation
Carrier lipid (20 nmol of PtdIns) was added to all samples and
dried under nitrogen. The dried lipid samples were resuspended in
50 Wl PIPkin bu¡er (Tris^HCl pH 7.4 50 mM, KCl 80 mM, Mg-
acetate 10 mM, EGTA 2 mM) containing 0.1 mg/ml disodium deoxy-
cholate by vigorous vortexing. Bacterially expressed human recombi-
nant PIPkin IIK enzyme (0.1 Wg) [16] was added to each sample.
Phosphorylation reactions were initiated by the addition of radiola-
belled ATP to a ¢nal concentration of 5 WM, 5 WCi [Q-32P]ATP per
sample. After incubation at 30‡C for 1 h, reactions were halted by
addition of 500 Wl 1:1 (v/v) CHCl3 :CH3OH followed by addition of
125 Wl 2.4 N HCl and 20 Wl Folch lipids from porcine brain as carrier
[11]. Phosphorylated lipids were then extracted as described previously
[12]. Phosphorylated lipids were resolved by TLC on silica-coated
glass plates (activated for s 30 min at 110‡C after dipping in a solu-
tion of 50% CH3OH, 1% potassium oxalate, 2 mM EGTA) in a
Whatman 3MM paper-lined tank pre-equilibrated at room temper-
ature (20^23‡C) for 2 h. Plates were developed in a solvent of
28:40:10:6 (v/v) CHCl3 :CH3OH:H2O:NH4OH, for 100^120 min,
and radioactive lipids visualised by autoradiography.
2.5. PtdInsP analysis
PtdInsP2 spots were excised from the silica plates, and either
counted immediately by scintillation counting (for quantitative assess-
ment) or processed further for analysis of individual phosphate moi-
eties. The latter was carried out ¢rst by deacylating [17] and then
deglycerating [18] the samples as described previously [19], though
deglyceration by sodium periodate was for 20 min as opposed to
the 90 min described, as this was found to be su⁄cient to convert
all the GroPIns(4,5)P2 to Ins(1,4,5)P3. Most InsP3 samples thus gen-
erated were dephosphorylated by recombinant type I inositol poly-
phosphate 5-phosphatase enzyme [20] for 60 min at 37‡C to yield
InsP2 and inorganic phosphate. Samples were separated by HPLC
on a Whatman Partisil-10 SAX column using a NaH2PO4 (pH
3.75) elution gradient from 0 to 0.75 M over 65 min. Samples were
collected at 45 s intervals for scintillation counting.
For some samples, deglyceration was not carried out and the
GroPInsP2s were analysed by PI-cellulose TLC. Samples were dis-
solved in 2 Wl 10 mM KH2PO4/20 mM HCl, centrifuged (10 000Ug,
1 min) and loaded onto a PI-cellulose plate in small (V0.4 Wl) ali-
quots, drying between aliquots. This was repeated, to ensure complete
loading, and plates were allowed to dry fully. Loaded plates were
placed in a TLC tank containing 50 ml 0.48 M HCl and left to resolve
for up to 45 min. Plates were removed and, after thorough drying,
exposed to X-ray ¢lm.
3. Results and discussion
3.1. Development of the PtdIns5P assay
Preliminary attempts to quantify platelet PtdIns5P were
hindered by inhibition of the type IIK PIPkin enzyme, which
was eventually traced to two sources. The ¢rst was due to
lipids present in the platelets that were inhibitory to the ¢nal
assay with recombinant PIPkin, and this problem was easily
eliminated by neomycin bead chromatography of the ex-
tracted lipids to purify the PtdIns5P. The second problem
was more variable, and was eventually tracked down to inter-
actions between some batches of the plasticware in common
use in our laboratory with acidic chloroform-based solvents.
Fig. 1. Solvents were dried in plastic microtubes prior to their use
in a standard PIPkin assay on 1 nmol PtdIns5P. Figures show auto-
radiographs of TLC plates to demonstrate PIP2 generation from
substrate by PIPkin IIK. Solvents were (a) CHCl3 and (b) theoreti-
cal lower phase (see Section 2). The three radioactive spots in (a)
are (from the bottom): origin, lyso-PtdIns(4,5)P2 and PtdIns(4,5)P2.
In (b) only the origin is radiolabelled.
Fig. 2. Qualitative HPLC analysis of lipids and standards by scintil-
lation counting of collected fractions. (a) 5-Dephosphorylated
[3H]Ins(1,4,5)P3 (open circles) and 5-dephosphorylated InsP3 gener-
ated from [Q-32P]-phosphorylated pure PtdIns5P (closed circles). (b)
5-Dephosphorylated [3H]Ins(1,4,5)P3 (open squares) and 5-dephos-
phorylated InsP3 generated from [Q-32P]-phosphorylated PtdInsP ex-
tracted from unstimulated platelets (closed squares).
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For example, Fig. 1 shows autoradiographs from a standard
PIPkin assay performed in dry tubes that had either been pre-
rinsed with pure chloroform (Fig. 1a) or with acidic lower
phase (from Bligh and Dyer [13], Fig. 1b). Clearly, plasticware
previously in contact with acidic lower phases causes inhibi-
tion of the enzyme assay. We did investigate carrying out all
procedures in glass, but the ¢nal enzyme assay proved too
variable under these conditions, probably due to adsorption
of the ATP, and possibly also of the PtdIns5P. However, we
put the neomycin bead chromatography ultimately to a fur-
ther purpose, as puri¢cation of the PtdInsP fractions on neo-
mycin beads removed any inhibitory substances derived from
the previous acidic lipid extraction procedures. The ¢nal elu-
tion solvent containing TEAB (see Section 2) was designed to
be su⁄ciently volatile that it could be removed by vacuum
centrifugation without any need for phase separations, thus
avoiding the need for any acids to be used after the neomycin
chromatography.
Prior to quanti¢cation of PtdIns5P in platelets, it was nec-
essary to establish ¢rmly that the only lipid to be phosphor-
ylated would be PtdIns5P. We con¢rmed the observations of
Rameh et al. [2] that in vitro the type II PIPkin phosphory-
lates PtdIns5P more than 100-fold faster than PtdIns4P, and
about 15 times faster than PtdIns3P if pure lipid substrates
are used at 10 WM (not shown). However, other lipids in the
extract (not removed by neomycin chromatography) may af-
fect this speci¢city. Any complication with PtdIns3P was
easily eliminated, as analysis of the GroPtdInsP2 by PI-cellu-
lose chromatography or InsP3 by HPLC derived from radio-
labelled PtdInsP2 formed during the assays revealed that it
was entirely the 4,5 and not the 3,4 isomer (see for example
Fig. 2). A more serious concern was that as there is likely to
be much more PtdIns4P present in platelets than PtdIns5P [2],
even the greater than 100-fold preference of the type II PIPkin
for PtdIns5P may not be su⁄cient to guarantee speci¢city of
the assay. However, the data (Fig. 2) show that with either
pure PtdIns5P or platelet lipid PtdInsP fraction as a substrate,
all the detectable 32P label generated by 5-dephosphorylation
of the Ins(1,4,5)P3 derived from the PtdInsP2 was recovered in
the Ins(1,4,)P2, and not as inorganic phosphate. These results
con¢rm that the PtdIns(4,5)P2 formed during the assay was
labelled in the 4, not the 5, position of the inositol ring. Thus
overall these experiments show that, under these conditions,
incorporation of radiolabel into a PtdInsP2 fraction truly al-
lows accurate quanti¢cation of PtdIns5P in the lipid extract
being assayed.
The assay was found to be linear with PtdIns5P quantities
up to 100 pmol (not shown). The radiolabelling e⁄ciency
varied between experiments, so in all platelet experiments
standard amounts of PtdIns5P were added to some samples
to check recovery from the starting material, and as a stan-
dardisation of each assay. Platelets were stimulated with
1 NIH-unit of carrier-free human thrombin at 37‡C for 1, 2,
5 or 10 min and the mass of PtdIns5P was compared with
these standards.
3.2. PtdIns5P measurement in platelets
Fig. 3 demonstrates the combined results from four experi-
ments investigating the presence of a time-dependent change
in PtdIns5P levels on thrombin stimulation. Resting platelets
had a PtdIns5P level of 15.77 þ 1.65 pmol/mg platelet protein,
expressed as a mean of four experiments þ S.E.M. After a
signi¢cant rise in PtdIns5P levels to 358 þ 104% of control
levels after 5 min thrombin stimulation, a fall is seen to
202 þ 67% control levels after a total of 10 min. This is in
contrast with earlier data for PtdIns, PtdIns4P and
PtdIns(4,5)P2 which are all found to decrease on thrombin
stimulation [10].
These data advance our understanding of four aspects that
relate to the physiological signi¢cance of the reaction cata-
lysed by type II PIPkins. Firstly, we con¢rm the presence,
in a naturally occurring cell (as opposed to cell cultures), of
the novel lipid, PtdIns5P. Secondly, we have for the ¢rst time
quanti¢ed the mass level of this lipid in a cell. Thirdly, the
levels of this lipid change when the cells, platelets, are subject
to a physiological stimulus, thrombin, which is well known to
have complex e¡ects on inositol lipid metabolism [8,9,21].
This is to our knowledge the ¢rst time agonist-stimulated
changes in PtdIns5P have been demonstrated.
Fourthly, the most interesting aspect of the data is the way
that the levels of PtdIns5P change. We have previously re-
ported that the activity of type II PIPkin in human platelets
changes during activation by thrombin [22]. Speci¢cally, the
enzyme is activated during the ¢rst few minutes of platelet
activation, and then the activity of the type II PIPkin returns
to nearer control levels during the next 5^10 min. At no time
during this stimulation have we found evidence for an inhibi-
tion of type II PIPkin activity, and as the time course in Fig. 3
suggests that PtdIns5P levels actually increase during this
time, it implies that the synthesis of this lipid has also been
stimulated as a result of thrombin receptor activation. At
present, we do not know if the route of synthesis of PtdIns5P
is by a PtdIns 5-kinase, or by 4-dephosphorylation of
PtdIns(4,5)P2, but either way, the data suggest that the syn-
thesis of PtdIns5P is tightly controlled, in turn implying that
the lipid may have a distinct physiological function. The mass
assay that we describe here will be a powerful tool in further
studies on this novel inositol lipid.
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Fig. 3. Quantitative analysis of PtdIns(4,5)P2 generated from
PtdIns5P extracted from platelets either unstimulated or thrombin-
stimulated for various time periods. Bars show mean percentages of
control levels for four experiments (2 min: three experiments)+
S.E.M. Control levels of PtdIns5P in the four experiments were
15.77 þ 1.65 pmol/mg protein. One-tailed Student’s t-test: *P6 0.05,
**P6 0.01 compared with control.
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